Bioidentical hormone therapy: a review

被引:82
作者
Boothby, LA
Doering, PL
Kipersztok, S
机构
[1] Columbus Reg Drug Informat Ctr, Columbus, GA USA
[2] Univ Florida, Coll Pharm, Drug Informat & Pharm Resource Ctr, Gainesville, FL USA
[3] Univ Florida, Coll Med, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Gainesville, FL 32610 USA
来源
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY | 2004年 / 11卷 / 03期
关键词
natural hormone therapy; bioidentical hormone therapy; estrogen therapy; drug compounding; progesterone;
D O I
10.1097/01.GME.0000094356.92081.EF
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: The terms "natural" or "bioidentical" hormone therapy (NHT) are used to describe hormone treatment with individually compounded recipes of certain steroids in various dosage forms, including dehydroepiandrosterone, pregnenolone, testosterone, progesterone, estrone, estradiol, and estriol. Based on the results of a person's salivary hormone levels, the final composition of the compounded dosage form is individualized to that specific person. Proponents claim that NHT is better tolerated than manufactured products. This paper is intended to review the concept of NHT and to determine whether there is sufficient scientific evidence to support its use. Design: A literature search was performed in Medline using the following MeSH terms and key words: drug combinations; progestational hormones; hormone replacement therapy; endometrium; estrogen replacement therapy; climacteric; menopause; estradiol; estrogens; progesterone; drug monitoring; and drug compounding. Current Contents, International Pharmaceutical Abstracts, Cochrane Database of Systematic Reviews, Lexis Nexis, Google, Medscape, MD Consult, and clinicaltrials.gov were searched with key words. Results: There are a few observational studies and clinical trials comparing conventional hormone therapy with bioidentical hormone therapy. Studies generally lacked adequate study design, including small sample sizes and comparison of inequivalent doses, to prove safety and efficacy. Little evidence was found to support individual zed hormone dosing based upon saliva hormone concentrations. Conclusion: Evidence suggests that, although individualized hormonal products may decrease some symptoms of menopause, it seems they have no proven advantage over conventional hormone therapies and their use is not supported by evidence regarding pharmacokinetics, safety, and efficacy.
引用
收藏
页码:356 / 367
页数:12
相关论文
共 109 条
[91]  
Stone DJ, 1998, J NEUROSCI, V18, P3180
[92]   Efficacy and safety of oral estriol for managing postmenopausal symptoms [J].
Takahashi, K ;
Manabe, A ;
Okada, M ;
Kurioka, H ;
Kanasaki, H ;
Miyazaki, K .
MATURITAS, 2000, 34 (02) :169-177
[93]   Role of P-glycoprotein in drug disposition [J].
Tanigawara, Y .
THERAPEUTIC DRUG MONITORING, 2000, 22 (01) :137-140
[94]   Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women [J].
Vehkavaara, S ;
Hakala-Ala-Pietilä, T ;
Virkamäki, A ;
Bergholm, R ;
Ehnholm, C ;
Hovatta, O ;
Taskinen, MR ;
Yki-Järvinen, H .
CIRCULATION, 2000, 102 (22) :2687-2693
[95]   THE MEASUREMENT OF HORMONES IN SALIVA - POSSIBILITIES AND PITFALLS [J].
VINING, RF ;
MCGINLEY, RA .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1987, 27 (1-3) :81-94
[96]   Low-potency oestrogen and risk of endometrial cancer:: a case-control study [J].
Weiderpass, E ;
Baron, JA ;
Adami, HO ;
Magnusson, C ;
Lindgren, A ;
Bergström, R ;
Correia, N ;
Persson, I .
LANCET, 1999, 353 (9167) :1824-1828
[97]   EFFECTS OF ESTROGENS AND PROGESTINS ON THE BIOCHEMISTRY AND MORPHOLOGY OF THE POST-MENOPAUSAL ENDOMETRIUM [J].
WHITEHEAD, MI ;
TOWNSEND, PT ;
PRYSEDAVIES, J ;
RYDER, TA ;
KING, RJB .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 305 (27) :1599-1605
[98]   Effects of the route of estrogen administration and exercise on hormonal levels in postmenopausal women [J].
Williams, CD ;
Dobridge, JD ;
Meyer, WR ;
Hackney, AC .
FERTILITY AND STERILITY, 2002, 77 (06) :1118-1124
[99]  
WILLIAMS CL, 1996, GOODMAN GILLMANS PHA, P1419
[100]  
WILSON JD, 1998, WILLIAMS TXB ENDOCRI, P802